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Skin is an immunological organ with a delicate immunological network that governs the homeostasis
and homing of the pro- and anti-inﬂammatory immune cells. Dysregulated immune response may result
in psoriasis, a common inﬂammatory skin disease. Inappropriate immune surveillance, on the other
hand, may cause the development of cutaneous lymphomas. Such homing of the immune cells likely
depends on the interactions of chemokine and its receptors. Chemokine receptors and their corre-
sponding chemokine ligands play key roles in the migration and localization of normal T cells in psoriasis
and neoplastic T cells in cutaneous T-cell lymphoma (CTCL). While important in immune cell homing in
psoriatic skin, chemokines and chemokine receptors may also be used for arrest, homing, and survival of
neoplastic T cells in CTCL. In this review, we discuss roles of chemokine receptors, including those of
CCR4 and CCR10 in the pathogenesis of CTCL, and of CCR6 in the pathogenesis of psoriasis. Targeting
chemokines and chemokine receptors may lead to more effective treatments in these two skin diseases.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Chemokines are small cytokines representing a large group of small
chemotactic proteins (w8e11 kDa in size) that guide the move-
ment of leukocytes to sites of inﬂammation.1 They bind and activate
cell-surface chemokine receptors, which belong to a large super-
family of seven-transmembrane-spanning, G-protein-coupled
receptors.1 Chemokines are categorized into four families (C, CC,
CXC, and CX3C) according to the spacing of key cysteine residues
near the N terminus of the chemokine.1 Chemokines and their
receptors are generally identiﬁed by their systematic names, con-
sisting of the family of the chemokine followed by the letter R for
receptor or L for ligand, with a number indicating their chrono-
logical order of discovery. The CC and CXC families comprise the
majority of known chemokines. Redundancies are present in che-
mokineechemokine receptor interactions because certain chemo-
kine receptors bind to multiple chemokines and vice versa.
Engagement of chemokine receptors with cognate chemokines cantology, Medical College of
Milwaukee, WI 53226, USA.
).
iwanese Dermatological Associatioactivate several downstream intracellular signaling pathways,
including calcium ﬂux as well as phosphoinositide-3 kinase (PI3 K)
and mitogen-activated protein kinase activation.
Upon ligation of chemokine receptors, these cell signaling
pathways result in diverse cellular processing such as cytoskeleton
reorganization, cell locomotion, and prosurvival signaling.2,3 Che-
mokines, as chemoattractant factors, are known for their ability to
stimulate directional migration of all classes of leukocytes. Diverse
subsets of T cells, such as Th1, Th2, Th17, Treg, and memory T cells,
express a regulated set of chemokine receptors that enable them to
differentially respond to speciﬁc chemokines. In the skin,
epidermal keratinocytes are able to express multiple chemokines
that can attract certain leukocytes, such as T cells or dendritic cells
(DCs), to migrate to the epidermis. In addition to their chemotactic
activity, chemokines enhance the ability of rolling and adhesion of
leukocytes to endothelial cells by increasing the afﬁnity and avidity
of b1 and b2 integrins on leukocytes in vitro and in vivo.
The skin provides a potent physical barrier and possesses
a sophisticated immunological defense system. The skin immune
system includes keratinocytes (being the most abundant cells in
the epidermis), epidermal Langerhans cells (LCs), dermal DCs, T
cells, endothelial cells, and ﬁbroblasts. Keratinocytes are able to
release several cytokines and chemokines both under baseline and
under activated conditions. A delicate balance between pro- andn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Malignant T cells in CTCL express certain number of chemokine receptors.
ECs, KCs, and LCs all generate a variety of chemokines that can regulate the (A) rolling
and (B) homing of malignant (and normal) T cells via dynamic EC adhesion, stimulated
chemotaxis toward epidermis, or movement toward activating LC, respectively. (C) LCs
produce chemokines that mediate their adhesion to T cells, forming Pautrier’s micro-
abscesses, thus stimulating activation of these T cells. (D) KC- and LC-derived che-
mokines can activate prosurvival pathways that prevent malignant T cells from
apoptosis. EC ¼ endothelial cell; IL ¼ interleukin; KC ¼ keratinocyte; LC ¼ Langerhans
cells.
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physiologic functions in the skin. Once disturbed and/or dysregu-
lated, the immune system of the skin may contribute to various
diseases because of defective tumor immunosurveillance, uncon-
trolled malignant T-cell growth, defective pathogen defense, and
exaggerated autoimmune reactions. Herein we examine two
diseases as examples where the roles for chemokines or their
receptors have been demonstrated through human and experi-
mental animal studies. First, mycosis fungoides (MF), a form of
CTCL, is characterized by the invasion of epidermis (and dermis)
with malignant T cells. Chemokines from keratinocytes, stromal
cells, and endothelial cells contribute to the preferential homing,
activation, and prosurvival of those malignant T cells. Second,
psoriasis, a common dermatological disease that affects 2e3% of
theworld’s populations and 0.1e0.5% of the Taiwanese populations,
causes a signiﬁcant morbidity in patients and is now known to be
associated with comorbidities, including metabolic syndrome,
obesity, and ischemic vascular disease. In psoriasis, dermal mixed
inﬂammatory inﬁltrates and presence of neutrophils in the
epidermis along with epidermal hyperproliferation are highly
characteristic. Chemokines from various skin cells mediate traf-
ﬁcking of different subsets of inﬂammatory cells when binding to
their corresponding receptors, forming a vicious proinﬂammatory
circle. Selective expression of chemokine receptors in Th17 cells
may provide good therapeutic targets in psoriasis.
Mycosis fungoides
Preface
MF is the most common form of CTCL. Patients with patches and
thin plaques usually have an indolent course. However, patients
with thick plaques and tumors, often extensive, face a poor clinical
prognosis. Sézary syndrome (SS) is a rarer leukemic variant of CTCL
(compared to MF) with striking skin ﬁndings that include eryth-
roderma as well lymphadenopathy. Malignant SS cells circulating
in the bloodstream have cerebriform nuclei and lose normal T-cell
surface receptors such as CD7 and CD26. MF is characterized by the
invasion of epidermis with malignant T cells. Chemokines from
keratinocytes, stromal cells, and endothelial cells contribute to the
preferential homing, activation, and, possibly, survival of malignant
T cells in both MF and SS. Recent work has indicated that MF and SS
arise from distinct populations of memory T cells called skin-
resident T cells and central memory T cells, respectively.4
Role of chemokines and chemokine receptors in neoplasia
Cancer cells take advantage of their upregulated chemokine
receptors to alter their organ-targeting metastatic spread. Mecha-
nistically, chemokine receptors can regulate the ability of cancer
cells to arrest on vascular endothelial cells.5 Moreover, chemokine
receptor engagement results in the activation of well-characterized
prosurvival pathways such as PI3 K and Akt (also known as protein
kinase B).6 Melanoma cells could utilize CXCR4 and CCR10 to
enhance cell survival and to escape killing in the absence of serum
or in the face of immune attack.7 CXCR4 inhibition renders those
melanoma cells susceptible to immunotherapy with cyclophos-
phamide and adoptive T-cell transfer.8 CCR10 activates PI3 K, which
mediates the inhibition of T-cell- and Fas-dependent killing of
melanoma cells in vitro. CXCR4 expression in basal cell carcinoma
contributes to tumor invasiveness through dermal matrix remod-
eling9 and angiogenesis.10 In T cells, chemokine receptor activation
suppressed the apoptosis induced by cyclohexamide or serum
deprivation.11,12 Thus, besides the chemotactic functions to enhance
metastasis, the prosurvival signals of chemokine receptors in thetumor cells may help these cells evade various forms of death
induced by chemotherapy or immunotherapy (Figure 1).
Skin microenvironment and homing of malignant T cells in MF
In skin, keratinocytes, the major cells in the epidermis, can release
multiple chemokines. Those chemokines can attract a wide variety
of leukocytes, including T cells, to the epidermis. Chemokines
produced by other cells, namely epidermal LCs and dermal DCs
bearing yet-unidentiﬁed skin antigens, may also play important
roles in attracting and activating malignant T cells (Figure 1).
Studies have found that DCs synthesize CCR4 ligands, which rapidly
promotemigration of normal T cells.13,14 A histopathological feature
of MF, Pautrier’s microabscesses, represents DC-malignant T-cell
conjugates that may result from these DC-derived chemokines.
Involvement of DC in CTCL pathophysiology has already been
extensively reviewed.15
Individual chemokines that may play a role in CTCL
In peripheral blood, onlyw25% of circulating T cells express CCR4.16
By contrast, MF as well as SS cells have increased CCR4 expres-
sions.16,17 CCL17, a CCR4 ligand, is produced by activated keratino-
cytes, endothelial cells, and DCs. Interestingly, CCL17 is upregulated
in the epidermis and serum of MF patients.18 The increased CCL17
in the skin may result in the preferential homing of MF cells to the
skin or aid in the survival of pre-existing skin-resident malignant T
cells. Clinically, increased CCL17 in blood may be a useful marker to
monitor the disease progression and treatment response in MF.19
Similarly, CCR10, which binds to CCL27 ligand, is only infre-
quently expressed on peripheral blood T cells, but it is considerably
enhanced in cutaneous lymphocyte antigen (CLAþ) skin-homing T
cells and in CTCL cells.20,21 Analogous to CCL17 (a CCR4 ligand),
CCL27 (a CCR10 ligand) is increased in the serum of MF/SS patients
andmay serve as a biomarker of disease activity22 and a therapeutic
marker after IFN-g and PUVA therapy.23 CCL27 is constitutively
synthesized in basal keratinocytes and is somewhat enhanced
under proinﬂammatorysituations. Thus, CCL27 may play a role in T-
C.-H. Lee, S.T.-Y. Hwang / Dermatologica Sinica 30 (2012) 128e135130cell epidermotropism inMF. Not only CCL27 can regulate cutaneous
homing, but it can also regulate nodal homing of T cells by rapidly
being released from activated keratinocytes to regional lymph
nodes via afferent lymphatics.24
CCR7 is critical for migration of maturing skin DCs and selected
T-cell subsets to the cutaneous draining lymph nodes.25 CCR7 is
found to be expressed atquite high levels in SS cells26 and may play
a role in the tropism of these cells to peripheral lymph nodes,
which constitutively synthesize the corresponding CCR7 ligand,
CCL21.
Keratinocytes, endothelial cells, and dermal ﬁbroblasts in
lesionalskinof CTCL showed stronger expression of eotaxin-3 than
did normalskin. CCR3(þ) lymphocytes were observed in some cases
of advanced CTCL. Both serum eotaxin-3 and eotaxin-1 levels of
CTCL patients at advanced stages were signiﬁcantly higher than
those of healthy individuals. The study suggested that interaction of
eotaxins and CCR3 may regulate the Th2-dominant tumor envi-
ronment, which is common in CTCL.27
CXCR4 may also be a crucial chemokine in homing of MF and SS
cells to skin. Loss of the cell-surface antigens, such as CD7 and
CD26, is a characteristic feature in MF and SS.28 Downregulation of
CD26, a dipeptidylpeptidase, is interesting in particular, since CD26
cleaves the critical amino terminus of several chemokines,
including CXCL12, and rapidly deactivates this chemokine in terms
of its ability to activate through CXCR4. Inactivation of CD26
promoted CXCL12-driven chemotaxis of cell lines derived from SS
patients.16 On the other hand, soluble CD26 was shown to inhibit
CXCR4-mediated migration. Thus, loss of CD26 on the SS cells may
provide a mechanism for their increased migration and survival in
the skin.
Further mechanistic and applied insights with respect to CCR4
and CCR10 in MF
CCR4 and CCR10 share similarities in their ability to direct the
trafﬁcking of T cells to the skin under inﬂammatory conditions.29,30
Both receptors are selectively expressed by “skin-homing” memory
T cells that bear surface carbohydrate ligands to E-selectin, an
adhesion protein that is characteristically expressed by inﬂamed
dermal blood vessels. Neutralizing antibodies to CCL27 (the CCR10




CCR2 Macrophages CCL2 Macroph
CCR3 T cells CCL5, CCL7, CCL8, CCL11 Macroph
Eosinophils
Other leukocytes
CCR4 T cells CCL17, CCL22 Keratino
Endothe
CCR7 T cells CCL21 Lymphat
DCs
CCR10 Skin-homing T cells CCL27 Keratino
Melanocytes Endothe
CXCR3 Memory T cells CXCL9, CXCL10, CXCL11 Keratino
NK cells Endothe
Fibroblas
CXCR4 Leukocytes CXCL12 Stromal
such as ﬁEndothelial cells
Many other cells
CTCL ¼ cutaneous T-cell lymphoma; DC ¼ dendritic cell; MF ¼ mycosis fungoides; NK ccontact dermatitis.30 The role of CCR4 and its ligand CCL17,
however, is less clear because optimal inhibition of cutaneous
inﬂammation in CCR4-deﬁcient mice required simultaneous
administration of CCL27 antagonists.29 Recent studies indicated
that CCR4 is crucial in the antigen-dependent skin inﬂammation, as
evidenced by the failure to accumulate ovalbumin (OVA)-speciﬁc T
cells in the skin.31 The facts that T-cell activation is achieved by the
adoptive transfer of CCR4-defected OVA-speciﬁc T cells and that
CCR4-negative Tcells home inefﬁciently to skin, but normally to the
gut, suggested a trafﬁcking defect to the skin as opposed to an
intrinsic homing defect in these cells.31 Besides the in vitro and
animal studies, several clinical observational studies suggest that
CCR4 is generally very highly expressed among CTCL cells inMF and
SS patients (Table 1).16,20,21,25,31e38
Targeting CCR4 and CCR10, the two chemokine receptors that
are often expressed by CTCL cells, may be an attractive therapeutic
approach to treat CTCL. Since normal circulatory T cells also
express those two receptors, it remains unknown whether tar-
geting these two receptors would result in unwanted immuno-
suppression. Nevertheless, a relatively small portion of the total T-
cell population expresses these two receptors. Thus, obliteration
of CCR4- and CCR10-positive T-cell populations would not likely
result in severe lymphopenia. Small-molecule antagonists of CCR4
and CCR10 (as present in CXCR4) have yet to be developed, but
antibodies targeting CCR4 that induce antibody-dependent
cellular cytotoxicity have already been reported.39,40 The
humanized anti-CCR4 antibody has been approved for use in
Japan for adult T-cell leukemia/lymphoma (ATLL). Furthermore,
bexarotene was reported to inhibit functional activation of CCR4,
suggesting a potential mechanism through which bexarotene is
effective in CTCL.41 Analogous to interleukin-2 (IL-2)ediphtheria
toxin fusion protein (denileukin diftitox), novel chemokineetoxin
fusion proteins may selectively target skin-homing T-cell pop-
ulations if they utilized chemokines such as CCL17 or CCL27 to
direct ligation to cutaneous T cells (Figure 1). Selective binding of
the chemokine receptor with a fusion toxin would result in
endocytosis of the chemokineetoxin and subsequent cell killing.
CCL17 molecules fused to the Pseudomonas exotoxin 38 have
already been shown to eliminate successfully the lymphoma cells
that express CCR4.42 Therefore, chemokineetoxin fusion proteins
may be useful as therapeutic agents in MF and/or SS.ion Biological role
ages CCL2/CCR2 axis in macrophage is critical
in CTCL disease progression32
ages and others CD30þ skin lymphoma expresses CCR333
cytes DCs CCR4 is important in the homing of T cell to the skin31
lial cells CCR4 expression is increased in CLAþ T cells
in patients with CTCL17
CCR4 expression is present in the process of large-cell
transformation in MF34
ic endothelial cells CCL21/CCR7 axis is important in the physiological
trafﬁcking of T cells to regional lymph nodes25,35
CCR7 expression is high in MF and SS cells36
CCR7may facilitate nodal invasion in CTCL and ATLL36,37
cytes CCR10 mediates T-cell homing to skin20
lial cells CCR10 expression is increased in MF and SS cells21





Downregulation of CD26, a protease that cleaves the
CXCL12 N terminus, may regulate skin homing16
ells ¼ Natural killer cells; SS ¼ Sezary syndrome.
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Chemokine receptors are likely to be involved in the selective skin
homing that characterizes CTCL. In addition to assisting in the ﬁrm
arrest of skin-homing T cells on dermal vascular endothelial cells,
they provide directional signals for T cells to migrate to speciﬁc
compartments of the skin, including the epidermis. Even after
localizing in skin, chemokine receptors may increase the survival of
the malignant T cells through activation of prosurvival pathways
such as PI3 K and Akt. The understanding of how chemokine
receptors participate in trafﬁcking and survival provides a prom-
ising rationale for the use of receptor inhibitors or antichemokine
receptor antibodies as novel therapeutic agents.
Psoriasis
Clinical manifestations of psoriasis
Psoriasis can be subdivided into several clinical subtypes: guttate,
inverse, palmoplantar, plaque, and erythrodermic psoriasis. Each
subtype has its own anatomic predilections, response to therapy,
and genetic signatures. Guttate psoriasis presents with small and
scaly papules, usually with a preceding streptococcal infection.
Inverse psoriasis tends to affect folds of the body, including the
axilla, umbilicus, and inguinal creases. Plaque psoriasis is the most
common subtype of psoriasis, characterized by red, well-
demarcated plaques covered with a silvery scale often involving
the extensor aspects of the body skin (Table 2).20,43e63
Histologically, in epidermis, often parakeratosis and occasion-
ally neutrophil accumulation occur in the subcorneal layer, known
as subcorneal pustules of Kogoj. The granular layer is often absent,
and there are usually striking epidermal acanthosis and a regular
elongation of the rete ridges. The suprapapillary plates are thin,
making the dilated dermal vessels occasionally grossly visible.
Recent studies have demonstrated that the skin is home to tens
of millions of resident effector memory Tcells.64 Even under clinical
resolution in psoriatic plaques, a genetic signature of psoriasis and
its proinﬂammatory state, a so-called "residual disease genomic
proﬁle," remains.65 Palmoplantar psoriasis may thus arise because
the hands and feet are constantly traumatized. A betterTable 2 Role of chemokines and chemokine receptors in psoriasis.
Chemokine receptors Expression Ligands Source
CCR2 Monocytes and macrophages CCL2 Basal
CCR4 Epidermal T cells CCL17 (TARC) KC45
Dermal CD3 þ T cells CCL22 (MDC) EC45
PBMCs
CCR5 Epidermal CD3 þ T cells CCL3 (MIP1a) Epider
Macrophages Upper
CCL5 (RANTES) Basal
CCR6 Epidermal T cells CCL20 (MIP3a, LARC) Suprab
PBMCs
CCR10 Many leukocytes CCL27 (CTACK) Basal
CXCR1 Epidermis CXCL8 (IL-8) Suprab
CXCR2 Suprabasal KC CXCL1 (GROa) Suprab
CXCL8 (IL-8) Suprab
CXCR3 Dermal CD3 þ T cells CXCL9 (Mig) KC Ma
Epidermal CD8þ cells EC45,59
Basal KC CXCL10 (IP10) KC43,4
pDC CXCL11 (ITAC) Psoria
CXCR6 None reported CXCL16 Basal
CX3CR1 EC CX3CL1 (Fractalkine) EC63
CLA ¼ cutaneous lymphocyte antigen; CTACK ¼ cutaneous T cell-attracting chemokine
IL ¼ interleukin; ITAC ¼ Interferon inducible T-cell alpha chemoattractant; KC ¼ keratin
derived chemokine; MIP ¼ macrophage inﬂammatory proteins; pDC ¼ plasmatoid dend
leukocytes; RANTES ¼ regulated and normal T cell expressed and secreted; TARC ¼ Thyunderstanding of the individual genetic signatures in the skin
microenvironment may provide more precise targets for treatment
in the future.
CCR6 and CCL20 in psoriasis
Th17 and CCR6 in psoriasis
Recently, a major shift of paradigm has developed in regard to the
role of different T-cell subsets in psoriasis. While Th1 cells,
producing interferon-gamma (IFN-g),were previously thought to
play the major role in regulating immune reactions in psoriasis,
both mouse and human data now indicate that Th17 cells,
producing IL-17 and IL-22 cytokines, likely have a greater patho-
genic role in regulating skin immunity in psoriasis. IL-23, a major
upstream player in the Th17 pathway, is an essential cytokine for
Th17 polarization and maintenance. Intradermal IL-23 injection
into wild-type (WT) mice results in psoriasis-like inﬂammatory
changes grossly and histologically.66e68 IL-23 is a heterodimeric
cytokine that shares its p40 subunit with IL-12 (a Th1 cytokine).69
Ustekinumab (Stelara), a biologic agent targeting the shared p40
component of IL-23, has shown substantial clinical efﬁcacy in
psoriasis,70 conﬁrming the role of Th17 cytokines in human psori-
asis. Because ustekinumab also blocks IL-12 and IL-17, it is difﬁcult
to exclude completely the role of Th1 cells in psoriasis. However,
preliminary reports of the efﬁcacy of anti-IL-17A antibodies in
human patients with psoriasis validate the role of the Th17
pathway in humans with psoriasis.71,72 Moreover, other human
studies suggest that the Th17 signaling pathway is a critical
mediator in the development and maintenance of psoriasis.73
These studies show that the number of Th17 cells and down-
stream effecter molecules, IL-17A, IL-17F, tumor necrosis factor
(TNF)-a, and IL-22 are increased in psoriatic skin lesions.73
Roles of different CD4 þ T-cell subsets in psoriasis are shown in
Figure 2. Circulating Th17 cells in adult human blood express CCR2,
CCR4, CCR5, CCR6, and CXCR3.67 Among those, CCR6 has been
described as a marker for Th17 cells both in human and in murine T
cells.74 Due to the paradigm shift to Th17 in psoriasis, several recent
studies have focused on the role of CCR6 in the pathophysiology of
psoriasis. CCR6 was initially discovered on both T cells75and
immature DCs.76,77 Recently, several research groups have shownBiological functions
KC43,44 Chemotaxis of monocytes, macrophages, and Th1 cells44
Th1 and Th17 trafﬁcking45e47
mis Chemotaxis of Th1 cells, monocytes, and DCs47,48
dermis45,48e51
KC43,48 Chemotaxis of eosinophils
asal KC46,52 Th17 trafﬁcking52
KC20,53,54 CLAþCD4þ or CLAþCD8þ cell chemotaxis20
asal KC43,55,56 Chemotaxis of PMN and T cells KC hyperproliferation57,58
asal KC55 Chemotaxis of PMN and T cells KC hyperproliferation57
asal KC43,55,56




KC EC62 Leukocyte chemotaxis and KC hyperproliferation
Th1 polarization63
; DC ¼ dendritic cell; EC ¼ endothelial cell; GRO ¼ Growth regulated oncogene;
ocyte; LARC ¼ liver activation regulated chemokine; MDC ¼ Human macrophage-
ritic cell; PBMC ¼ peripheral blood mononuclear cells; PMN ¼ polymorphonuclear
mus and activation regulated chemokine.
Figure 3 Roles of chemokines and chemokine receptors in psoriasis. Circulating CCR4-
and CXCR3-expressing Th1 cells migrate into epidermis from dermis through inter-
action with KC-derived CCL17 and/or CCL22, the CCR4 ligands, and CXCL9, CXCL10,
and/or CXCL11, the CXCR3 ligands. CCR5-expressing CD3 þ T cells move to epidermis
via interaction with CCL3 and KC-derived CCL5, both CCR5 ligands. The selectivity of
CCL20 for CCR6 allows recruitment of circulating CCR6-expressing cells, including Th17
cells and gdT cells that express Th17 cytokines, as well as LCs into inﬂamed epidermis.
CCR10-expressing CLAþ, CD4þ, and CD8 þ T cells migrate into epidermis via KC-
derived CCL27, the CCR10 ligand. CXCL8 is a common ligand for both CXCR1 and
CXCR2, and is a potent chemoattractant for neutrophils. CCR2-expressing monocytes
and Mfs migrate into epidermis via KC-derived CCL2, the CCR2 ligand. The pDCs, which
also express CXCR3, also migrate toward inﬂamed epidermis. CLA ¼ cutaneous
lymphocyte antigen; EC ¼ endothelial cell; KC ¼ keratinocyte; LC ¼ Langerhans cell;
Mf ¼ macrophage; pDC ¼ plasmatoid dendritic cell.
Figure 2 Roles of CD4 þ T-cell subsets in psoriasis. Th cell subsets and Treg cells are
differentiated from naive T cells. Under homeostatic conditions, the activation of Th
cells is, in part, dependent on Treg cells. T-cell-mediated immune response is kept in
delicate balance. In case of psoriasis, this homeostatic balance is disrupted, leading to
Th1 and Th17 responses.
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and in the pathogenesis of psoriasis (as described below). CCR6
was initially shown to mediate adhesion and arrest of T cells to
endothelial cells under physiologic shear stress.78 In psoriatic
patients, peripheral CCR6-expressing Th17 cells are increased both
in skin and in blood.52 Moreover, current models suggest that IL-23
from DCs maintain dermal CCR6-expressing Th17 cells.79 CCR6
appears to be essential for the development of a psoriasiform
phenotype in mice since IL-23 injection in skin of WT mouse,80 but
not in that of CCR6 knockout mice, results in psoriasis-like skin
lesions,80 indicating that CCR6 chemokine axis may be a provisional
target in psoriasis.66 Of note, anti-CCR6 antibody reduced the
severity of collagen-induced arthritis, a model for rheumatoid
arthritis.81 While no small-molecule inhibitors of CCL20 or CCR6
have yet been described, new in silicotechniques82 that have
successfully identiﬁed drug-like CXCR4/CXCL12 antagonists83 may
soon allow the rational design of CCR6/CCL20 antagonists.
CCL20 and psoriasis
CCL20 is the only known chemokine ligand for CCR684; however,
human b-defensin 2 (hBD2) also induces chemotaxis of leukocytes
via CCR6.85 CCL20 is constitutively expressed at low levels in
epidermal keratinocytes and dermal endothelial cells.84 Its
expression is strongly enhanced by proinﬂammatory cytokines,
including TNF-a, IL-1a, IL-17, and IFN-g.78,84 In psoriatic skin
lesions, CCL20 is robustly expressed throughout the epi-
dermis52,66and may be crucial in recruiting CCR6-expressing T cells
into inﬂamed epidermis from underlined dermis, whereas CCL20
expressed by dermal endothelial cells may serve to arrest CCR6-
positive leukocytes from the blood stream. Furthermore, produc-
tion of CCL20, which is enhanced by CCR6 þ Th17 cells producing
IL-17, positively reinforces the recruitment of more CCR6 þ Th17
cells (Figure 3).Other chemokines that may possibly be involved in psoriasis
Neutrophils and CXCL8
CXCL8, a neutrophil chemoattractant (chemokine), is notably
increased in psoriatic skin by quantitative polymerase chain reac-
tion (qPCR).T cells and CCR10
Analogous to that occurs in MF, more than 90% of the T cells in
psoriatic skin expresses CCR10, a receptor for the chemokine ligand
CCL27 that is constitutively expressed in the epidermis. TNF-
aupregulates CCL27 expression in keratinocytes both inmice and in
humans, and therefore recruits more effector memory T cells to the
skin.20
DCs and CCR6
In addition to T cells, LCs also express CCR687 and are strongly
migrate toward CCL20.87 Komine et al88 showed that the number of
CD1aþCD11cþlangerinþ DCs in lesional skin was increased
compared with those in uninvolved skin. CD11cþ mature DCs
harvested from the dermis of psoriatic skin lesions generate IL-
23,89 a key factor that maintains Th17 differentiation. Another
subset of dermal DCs, TNF/iNOS-producing DCs,86 also plays a role
in the development of psoriasis through production of IL-20.90,91
Besides DCs, dermal macrophages show increased expression of
CCR2,44 CCR5,48 and CXCL946,61 in psoriatic skin lesions. CCR6 may
not be present on mature macrophages; however, it may be
involved in the development of macrophage lineage.92 Of note, in
Rag1-deﬁcient mice, which lack both T and B cells, IL-23 injection
in the ﬁrst 5e6 days of treatment (but not after that) resulted in
a psoriasiform skin phenotype along with production of IL-22 and
IL-17A, suggesting that T cells are not essential in the initial
responses to IL-23.66 Therefore, LCs, DCs, and macrophages may
also be able to induce psoriasis-like features initially in the absence
of T cells, although it appears that expression of T cells is required to
maintain expression of IL-17A and IL-22 after initial induction of
psoriasiform dermatitis.66
Role of gd T cells in psoriasis
While there appears to be a convincing role for conventional abT
cells in psoriasis, the role of unconventional T cells, including gd T
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studies show that gd T cells are increased in numbers in psoriatic
skin lesions.93,94 Interestingly, peripheral gd T cells express high
levels of IL-23 receptor, and they are activated by IL-1b and IL-23 to
produce IL-17 and IL-22.95 Furthermore, a new study describes
a motile population of dermal gd T cells that express low-
intermediate levels of CCR6, CXCR6, and IL-17.96 Using the IL-23
skin injection psoriasis mouse model,66,68,97 Mabuchi et al98
showed that IL-22, IL-17A, and IL-23 receptor were highly
enriched in a population of CCR6þ, T cell receptor (TCR) gd-low
expressing (GDL) T cells that accumulated in skin with marked
inﬁltration of the epidermis. Large numbers of CCR6þ cells were
detected at or above the level of the epidermal basement
membrane 5 days after repeated IL-23 injections, in parallel with
increased GDL cells in the epidermis. TCR d-deﬁcient mice (lacking
gdT cells) had diminished ear swelling and impaired expression of
IL-22 and IL-17A in the epidermis following IL-23 injection, sug-
gesting that gdT cells play a critical role in IL-23-mediated psor-
iasiform dermatitis, although the clinical relevance of gdT cells
requires further investigation. Subsequently, we have shown that
treatment of mice with anti-CCL20 mAb markedly reduces traf-
ﬁcking and IL-22 production by GDL T cells in the IL-23 skin
injection model,99 raising the possibility that drugs or antibodies
targeted at the CCR6/CCL20 axis may be therapeutically beneﬁcial
in psoriasis or other Th17-mediated autoimmune disease.80
Role of b-defensin 2 in psoriasis
In addition to CCL20, hBD2 also signals through CCR6.85 Defensins
are small (3.5e4.5 kDa in size) antibacterial peptides that are
primarily expressed by epithelial cells in the skin, kidney, and
tracheaebronchial lining. Defensins exhibit a broad spectrum of
antimicrobial activity against Gram-positive and Gram-negative
bacteria, fungi, and viruses. The defensin hBD2 is highly expressed
in the epidermis of psoriatic skin.100 Increased copy numbers of b-
defensin gene are associatedwith susceptibility to psoriasis in Dutch
and German populations,101 and serum levels of hBD2 may be
a useful marker for disease activity in psoriasis.100 Increased hBD2
production in psoriasis may act in concert with CCL20 to attract
requisite populations of CCR6þ cells, including Th17 cells.
CXCR3 in dermal CD3þ lymphocytes
CXCR3 is upregulated on dermal CD3þ lymphocytes. The corre-
sponding ligands CXCL9, CXCL10, and CXCL11 (also known as Mig,
IP10, and ITAC, respectively) are increased in psoriatic skin
lesions.45,59 CXCR3 is involved in transendothelial migration of T
cells and T-cell trafﬁcking to psoriatic epidermis.45
CCR5 in epidermal T cells and dermal macrophages
CCL5, or RANTES, one of the ligands for CCR5, is highly expressed in
psoriatic skin lesions.49,51 Calcipotriol, an active vitamin D3
analogue, can inhibit CCL5 production in culturednormal epidermal
keratinocytes.49 Furthermore, CCR5 expression was considerably
higher in both epidermal Tcells and dermalmacrophages in lesional
psoriatic skin comparing to that measured in nonlesional skin.48
Although these results suggested a potential role for CCR5 and
CCL5 in the inﬂammatory cascade of psoriasis, the CCR5 inhibitor
SCH51125 yielded neither clinical beneﬁt nor signiﬁcant differences
in CCR5 expression during psoriasis clinical trials.48
Therapeutic targets of chemokines and chemokine receptors in
psoriasis
CXCR3 small-molecule antagonist T487
The CXCR3 small-molecule antagonist T487 was found to relieve
symptoms and hinder the progression of rheumatoid arthritis,inﬂammatory bowel disease, multiple sclerosis, and psoriasis.102
Although a phase II trial of T487 in psoriasis was performed in
2003,103 its use in psoriasis has not been reported since that time.
CXCL8 humanized neutralizing monoclonal antibody ABX-IL8
CXCL8 (also known as IL-8), a common ligand for CXCR1 and CXCR2,
represents a potent chemoattractant for neutrophils. It likely plays
a role in recruitment of neutrophils to the epidermis and corniﬁed
layer, leading to Munro abscesses, a characteristic feature in
psoriasis. ABX-IL8 is a fully humanized neutralizing monoclonal
antibody against CXCL8 that was evaluated in a phase II clinical trial
for psoriasis. However, ABX-IL8 was not effective in reducing PASI
scores.102 While the reason for the lack of clinical effect is unclear,
this might have resulted from the presence of other redundant
neutrophil-attracting CXCR1/CXCR2 ligands such as CXCL1, CXCL2,
CXCL3, CXCL5, and CXCL6.80
Short summary
Multiple chemokines and chemokine receptors maybe involved in
the development and progression of psoriasis. The redundancy of
the chemokine systemmakes therapies targeting single chemokine
or chemokine receptor challenging. However, in mouse models of
psoriasis, therapeutic agents inhibiting the CCR6 pathway have
demonstrated efﬁcacy. Moreover, the mice lacking CCR6 are
remarkably resistant to induction of psoriatic phenotype following
IL-23 injection. Both CCL20 and hBD2 may recruit CCR6-expressing
cells into inﬂamed epidermis. Given the possibility that these two
peptides redundantly recruit inﬂammatory cells via CCR6, targeting
CCR6 itself rather than its ligands, CCL20 or hBD2, with a mono-
clonal antibody or small molecule would seem to be a better tar-
geting strategy in psoriasis.
Conclusion
Chemokines and chemokine receptors have long been recognized
for their chemotactic activities with respect to many leukocytes,
including Th1 cells, Th17 cells, macrophages, DCs, neutrophils, etc.
Many of those chemokines and chemokine receptors are present in
psoriatic skin and contribute to dermal inﬂammation and, perhaps
indirectly, to epidermal keratinocyte hyperplasia in psoriasis. Pref-
erential expression of CCR6 in Th17 cells makes CCR6 a rational
therapeutic target in psoriasis. In neoplastic CTCL, malignant T cells
proliferate, accumulate, and "home" to the skindprocesses that
likely result from increased expression of chemokine receptors such
as CCR4 and CCR10 in neoplastic T cells. Not only interactions of
chemokines and chemokine receptors direct trafﬁcking in those
neoplastic cells, but those cells may also take advantage of the
chemokine pathways to provide prosurvival signals and evade
apoptosis by various assaults. The recent approval of an anti-CCR4
antibody for ATLL in Japan that has efﬁcacy in CTCL provides deﬁn-
itive evidence that targeting chemokine receptors in neoplastic
diseases can have clinical utility. Further attempts are warranted to
identify CCR6 (and possibly other chemokine receptor) antagonists
thatmay be useful in psoriasis and other autoimmune skin diseases.
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